ArticleOncotarget2018
Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- The incidence and risk factors of venous thromboembolism in patients with pancreatic cancer: a systematic review and meta-analysis.Journal of gastrointestinal oncology · 2025Article
- The effects of coagulation factors on the risk of lung cancer: a Mendelian randomization study.Discover oncology · 2025Article
- Review
- Pancreatic Cancer and Venous Thromboembolism.International journal of molecular sciences · 2024Review
- Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer - An Overview.Current treatment options in oncology · 2023Review
- Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care.Cancers · 2023Review
- The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma.BMC cancer · 2023Article
- Oncogenes and cancer associated thrombosis: what can we learn from single cell genomics about risks and mechanisms?Frontiers in medicine · 2023Review
- Pathophysiology of Coagulation and Emerging Roles for Extracellular Vesicles in Coagulation Cascades and Disorders.Journal of clinical medicine · 2022Review
- Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer.Cancer medicine · 2022Article
- Cancer-associated venous thromboembolism.Nature reviews. Disease primers · 2022Review
- Article
- Burden of venous thromboembolism in patients with pancreatic cancer.World journal of gastroenterology · 2021Review
- Platelet-Derived Procoagulant Microparticles as Blood-based Biomarker of Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment.Cancer immunology, immunotherapy : CII · 2021Article
- Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.Blood advances · 2021Article
- [Tissue factors and venous thromboembolism in cancer patients].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2020Article
- Article
- Mechanisms and biomarkers of cancer-associated thrombosis.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Differential biomarker profiles between unprovoked venous thromboembolism and cancer.Annals of medicine · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thrombo-embolic events (VTE) frequently occur in patients with pancreatic ductal adenocarcinoma (PDAC) and contribute to high morbidity and mortality.
objectivesTo determine whether VTE biomarkers are related to cancer, inflammation or precancerous states and to assess their relevance to predict VTE in PDAC. PATIENTS AND
methodsWe compared VTE biomarkers in patients with PDAC (
resultsFactor VIII, D-dimers, von Willebrand factor, free tissue factor pathway inhibitor and microvesicle-tissue factor (MV-TF) activity were higher in PDAC patients compared to patients with IPMN or chronic pancreatitis. PDAC patients with metastasis presented higher D-dimers and MV-TF activity compared to patients with localized lesions, but elevation of D-dimers was dependent on tumor size. In multivariate analysis, elevated D-dimers (≥2.16 µg/mL) or MV-TF activity (≥2.37 pg/mL) were significant risk factors for VTE in PDAC patients, after adjustment for age and sex (HR 4.9 [1.0-23.1] or HR 10.5 [1.5-72.4], mean [interquartile range], respectively). Cumulative probability of VTE at 6 months was higher in patients with elevated D-dimers (56.3% vs 15.6%,
conclusionsVTE biomarkers including D-dimers and MV-TF activity are not related to inflammation but rather to cancer process and dissemination. D-dimers and MV-TF activity are associated to future VTE in PDAC patients and could help identify patients who could benefit from thromboprophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.